Blockchain Registration Transaction Record

Oncotelic's AI Platform Integrates 28M Abstracts to Transform Drug Discovery

Oncotelic Therapeutics integrates 28M scientific abstracts into its PDAOAI AI platform, aiming to revolutionize drug discovery and compete with big pharma. Learn how this small biotech is leveraging AI.

This matters because the integration of 28 million scientific abstracts into Oncotelic's PDAOAI platform represents a leap in AI-driven drug discovery, enabling faster identification of drug candidates and repurposing opportunities. For patients, this could mean quicker access to treatments for rare and neglected diseases that large pharma often ignores. For the industry, it demonstrates that small biotech firms can leverage AI to compete with giants, potentially lowering drug development costs and accelerating innovation. Investors should watch how Oncotelic's platform translates into clinical progress and partnerships, as success could validate a new model for pharmaceutical R&D.